Table 2.

Distribution of splicosomal mutations among patients with hematologic malignancies.

Disease	Estimated mutational frequencies
	SF3B1	U2AF1	SRSF2	ZRSR2
CLL	15%	NF	NF	NF
Low risk MDS RARS/RCMD-RS	20–28% 65–73%%	5–6% 1–3%	5–8% 5–6%	1% 5%
CMML	3–5%	8–15%	27–40%	8%
RAEB1/2, sAML	2–5%	6–16%	4–6%	6%
AML	2–3%	1–8%	1–3%	1%

Literature: NF not found; Literature CLL (Rossi D et al, 2011; Quesada V et al, 2012), MDS and AML (Visconte V et al, 2011; Makishima H et al, 2012; Yoshida K et al, 2011; Graubert TA et al, 2011; Papaemmanuil E et al, 2011). CMML (Yoshida K et al, 2011, Makishima H et al, 2012; Muramatsu H et al, 2011; Abu Kar S et al, 2012), ZRSR2 (Yoshida K et al, 2011)